Quote:

---

All posts using that dirty word should be deleted.

Quote:

---

Imagine we sit at $8 and BP offers $25

---

By the time we hit $8 we'll have a very nice set of clinical data for cancer ,should be starting other Phase 2 trials and nicely into revenue. The pressure will be off financially and the forest will be cleared so shareholders can see the trees (revenue potential in cancer).

I think the majority (even if slight) of shareholders would vote against it. If the FDA accepts an early BLA submission for cancer then that $25 would seem ridiculously low. As I said earlier the potential should outrun any offers.

---